Consistent with our findings, liraglutide reduced IL-1β and TNF-α levels in a rat model of PTZ-induced epilepsy [49], highlighting the NLRP3 inflammasome complex as a potential target for antiepileptogenic treatments. Here, NLRP3 is linked to epilepsy.